Skip to main content
. 2022 Feb 4;106:108570. doi: 10.1016/j.intimp.2022.108570

Fig. 1.

Fig. 1

Schematic representation of regdanvimab binding to the receptor-binding domain of SARS-CoV-2. Steric hindrance caused by regdanvimab prevents SARS-CoV-2 binding to the angiotensin-converting enzyme 2 receptor on host cells, blocking virus entry. ACE2, angiotensin-converting enzyme 2; Fab: fragment antigen binding; Fc: fragment crystallizable; RBD, receptor-binding domain; S, spike protein.